Immunology & Inflammation Biotech Apogee Plans IPO to Demo Dosing Edge in Eczema
MedCity News
JUNE 25, 2023
Apogee Therapeutics is planning an IPO to fund clinical development of biologic drugs that could offer dosing advantages over currently available immunology and inflammation drugs. Its lead program is being prepared for Phase 1 testing in atopic dermatitis, or eczema.
Let's personalize your content